Alar Pharmaceuticals Inc.
TPEX:6785 Rapport sur les actions
Capitalisation boursière : NT$9.9b
Alar Pharmaceuticals Gestion
Gestion contrôle des critères 0/4 Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Yung-Shun Wen
Directeur général
Pourcentage du salaire du PDG n/a Durée du mandat du directeur général no data Propriété du PDG 0.9% Durée moyenne d'occupation des postes de direction pas de données Durée moyenne du mandat des membres du conseil d'administration pas de données
Mises à jour récentes de la gestion
Alar Pharmaceuticals Inc., Annual General Meeting, May 21, 2024 Mar 07
Less than half of directors are independent Nov 16
Less than half of directors are independent Apr 27 Alar Pharmaceuticals Inc., Annual General Meeting, May 25, 2021
Afficher toutes les mises à jour
Alar Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Investor sentiment deteriorates as stock falls 16% Aug 06
Alar Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 31
Investor sentiment deteriorates as stock falls 17% Jul 10
Investor sentiment improves as stock rises 16% May 20 Alar Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 28
Investor sentiment improves as stock rises 16% Apr 04
Alar Pharmaceuticals Inc., Annual General Meeting, May 21, 2024 Mar 07
New minor risk - Shareholder dilution Feb 18
New major risk - Share price stability Jan 24
Now 21% undervalued Jan 22
Now 20% undervalued Nov 09
Now 22% undervalued Oct 20
Less than half of directors are independent Nov 16
Less than half of directors are independent Apr 27
Alar Pharmaceuticals Inc. Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 Jan 13 Alar Pharmaceuticals Inc., Annual General Meeting, May 25, 2021
We're Hopeful That Alar Pharmaceuticals (GTSM:6785) Will Use Its Cash Wisely Jan 13
PDG Dr. Yung-Shun Wen, Ph D., is Chief Executive Officer & Director of Alar Pharmaceuticals Inc. He has experiences in the pharmaceutical industry When he was a director of RD department in a well-known pharma ... Show more
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
